HUTCHMED to Present Positive Savolitinib Gastric Cancer Data at ASCO, Supporting Priority Review NDA
summarizeSummary
HUTCHMED will present positive Phase II data for savolitinib in gastric cancer at ASCO, detailing the results that led to its priority review NDA in China.
check_boxKey Events
-
Positive Savolitinib Phase II Data
Pivotal Phase II study of savolitinib in MET-amplified gastric cancer met its primary endpoint with an an objective response rate (ORR) of 32.3%, exceeding the pre-specified efficacy threshold.
-
NDA Granted Priority Review
The positive clinical data supported the New Drug Application (NDA) submission to China's NMPA, which was accepted and granted priority review in December 2025.
-
ASCO Presentation
New and updated clinical data for savolitinib, fruquintinib, and surufatinib will be presented at the 2026 ASCO Annual Meeting, including a rapid oral session for savolitinib.
-
Stock Trading Near 52-Week Low
This positive clinical development comes as HUTCHMED's stock is trading near its 52-week low, potentially offering a boost to investor sentiment.
auto_awesomeAnalysis
HUTCHMED announced strong clinical data for savolitinib in gastric cancer from a pivotal Phase II study, which met its primary endpoint with a 32.3% objective response rate. This data supported the New Drug Application (NDA) that was accepted for priority review in China in December 2025. The presentation at the ASCO Annual Meeting provides further validation and visibility for this key pipeline asset, potentially boosting investor confidence, especially with the stock currently trading near its 52-week low.
At the time of this filing, HCM was trading at $12.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $11.72 to $19.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.